UTime Limited Partners with Dr. Ehud Baron to Pioneer AI-Driven Health Solutions
UTime Limited, a leading company in the international healthcare sector, has announced the commencement of a comprehensive financial and legal due diligence analysis of Bowen Therapeutics Inc. The acquisition of Bowen Therapeutics is a significant step for UTime in expanding its presence in the innovative medical products market, aiming to strengthen the company’s position and advance medical technology.
Bowen Therapeutics plays a crucial role in UTime’s strategy, with a strong reputation in the medical technology sector. The company’s research and development potential and innovative technologies are widely recognized in the industry. Bowen Therapeutics’ contribution to the development of a smallpox vaccine has led to the creation of revolutionary technologies that are now used in healthcare worldwide. With advanced technologies and research and development capabilities, UTime aims to enhance its technological innovations and accelerate its expansion in the healthcare sector.
The financial and legal due diligence analysis of Bowen Therapeutics is a key component for UTime to secure its investment and gather data to support the acquisition decision. The financial analysis will include an assessment of financial statements, asset and liability position, and cash flow. UTime will also verify tax documentation and accounting systems to ensure compliance with international financial reporting standards. The legal due diligence will focus on issues such as management structure, legality of contracts, intellectual property rights, and ongoing legal proceedings to mitigate potential legal complications.
The due diligence analysis is a complex and multi-faceted process that will allow UTime to thoroughly understand Bowen Therapeutics’ operations and financial situation, assess risks and potential opportunities, and make decisions in line with the company’s long-term development strategy.
UTime Limited, established in 2008, provides affordable mobile devices to consumers worldwide and helps low-income individuals in established markets such as the United States and emerging markets like India, South Asia, and Africa access the latest mobile technology. Since 2024, UTime has been working towards transforming the healthcare and wellness sector by implementing innovative medical technologies in wearable products. Through cutting-edge research and strategic partnerships, UTime aims to provide effective solutions for disease prevention and health management on a global scale.
The statements in this press release regarding future expectations, plans, and prospects may constitute “forward-looking statements” under the Securities Litigation Reform Act of 1995. Actual results may significantly differ from those indicated in the forward-looking statements, due to various factors discussed in the Risk Factors section of the Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on July 30, 2024. All forward-looking statements in this press release are current as of the date of publication, and the company does not undertake to update any forward-looking statements due to the emergence of new information, future events, or other reasons.
For more information, please contact Eaky Tan at [email protected].
